Table 2.

Relevant clinical characteristics of the 49 patients with CD

Disease classification (as per Montreal criteria)
Age at diagnosis
A1 16 y or below	5 (10%)
A2 17–40 y	34 (71%)
A3 above 40 y	9 (19%)
Location
L1 ileal	11 (23%)
L2 ileocolonic	17 (35%)
L3 colonic	20 (42%)
L4 upper GI	3 (6%)
P perianal	11 (23%)
Behavior
B1 non-stricturing/penetrating	29 (60%)
B2 stricturing	11 (23%)
B3 penetrating	8 (17%)
Median duration since CD diagnosis (range) y	14 (1–46)
Active disease, as per:
Disease activity score
HBI ≥ 5	20 (42%)
Median HBI (range)	4 (1–18)
Intestinal inflammation
Faecal calprotectin ≥ 150 µg/g	25 (52%)
Median calprotectin (range) µg/g	255 (30–1800)
Systemic inflammation
CRP ≥ 5 mg/l	13 (27%)
Median CRP (range) mg/l	2.4 (0.4–45)
Low iron status (serum ferritin ≤ 30 g/l)	8 (17%)
Prior bowel resection for CD	19 (40%)
Documented psychological comorbidity	15 (31%)
Current therapy
Corticosteroid use	6 (13%)
Immunomodulator use	26 (54%)
Anti-TNF use	12 (25%)
Smoking status
Current smoker	8 (17%)
Ex-smoker	19 (40%)
Never smoked	21 (43%)

CD: Crohn’s disease; y: years; TNF: tumour necrosis factor; GI: gastrointestinal; HBI: Harvey–Bradshaw Index; CRP: C-reactive protein.